Download Patent Ductus Arteriosus

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Electrocardiography wikipedia, lookup

Transcript
Chris Burke, MD
PATENT DUCTUS ARTERIOSUS
What is the Ductus Arteriosus?
Ductus Arteriosus
 Allows blood from RV to bypass fetal lungs
 Between the main PA (or proximal left PA)
and the descending thoracic aorta
 Maintains patency in utero by low O2 tension
and high circulating prostaglandin levels
Ductus Arteriosus
 During final trimester, ductus becomes much
less sensitive to prostaglandins
 Following birth, rise in O2 tension and lack of
placental prostaglandins usually results in
closure
 Usually complete by 12-24 hours, but
sometimes days-weeks
 Becomes ligamentum arteriosum
Patent Ductus Arteriosum
 Roughly 1 out of 1200 live births, more
common in premature infants thought to
be related to immature ductal wall being less
sensitive to O2 tension
 Constitutes 7% of congenital heart defects
 Desirable in some defects including many
cyanotic heart lesions; this has led to the use
of PGE4 clinically
Pathophysiology
 Shunt volume
determined by the size
of ductus and ratio of
pulmonary to systemic
vascular resistance
 PVR declines over first
several weeks of life,
increasing left-to-right
shunt across PDA
 Excessive shunting can
lead to right heart
failure
Pathophysiology
 Over time, pulmonary
vascular obstructive
disease will develop
 Eisenmenger syndrome
is the end result, when
shunting reverses to
right-to-left; this is
associated with
irreversible pulmonary
hypertension and
cyanosis, eventually
leading to RV failure
Morphologies
Clinical Manifestations
 Infants with large shunt volume may develop
CHF leading to tachypnea, tachycardia, and
poor feeding
 Physical exam findings include: widened
pulse pressure and continuous “machinery
murmur”, heard best along the left sternal
border radiating to the back
Clinical Manifestations
 CXR may show increased pulmonary
markings and left heart enlargement
 EKG may have LVH and/or left atrial
enlargement
 Echo diagnostic method of choice
 Diagnostic cardiac catheterization generally
only performed in adults to evaluate for
pulmonary hypertension
<>
Treatment
 Pharmacologic
 Endovascular
 Surgical
Considerations
 Closure is performed for all symptomatic
patients with left-to-right shunt
 Indications for closure in Asx patients:
 signs of left heart volume overload
 reversible pulmonary hypertension
 murmur
 Closure NOT recommended when
Eisenmenger physiology is present or PDA is
silent (controversial)
Considerations
 In patients with PVR greater than 8 Woods
Units, closure is generally not recommended
 This is especially true when right-to-left or bidirection flow is present or elevated PVR not
reversed with high O2 or iNO
 This can lead to catastrophic RV failure, due
to loss of “pop-off” mechanism
Pharmacologic Closure
 Indomethacin, a prostaglandin inhibitor, can
be used to close a PDA
 0.1-0.2 mg/kg IV at 12 or 24- hour intervals for
a total of three doses
 Rarely effective in term infants
 80% effective in premature infants
Surgical Closure
 Dates back to 1939
 Generally reserved for infants and children
with lesions deemed unsuitable for
percutaneous closure
 Good choice for larger PDAs (~ 8mm)
 Posterolateral thoracotomy classically, but
VATS approach described
Percutaneous Closure





First performed in 1967
Access via femoral artery or vein
Most commonly use coils or occlusion devices
Proven benefit with PDAs < 3mm
Major limitation of these techniques is ductus
size in one study a PDA diameter greater
than 4mm had a 24-fold increased risk of
incomplete closure
 Morphology is another significant issue!
Percutaneous Closure
Percutaneous Closure
Surgical Closure Still Has a
Role
 Galal et al reported a 20% conversion or
failure rate with 236 attempted percutaneous
closures
 Hsiao et al reported reduced number of
ventilator days and improved outcomes in
VLBW (<1500 g) premies that underwent
early (<14 days old) versus late (>14 days old)
surgical repair
Management Summary
 Who gets closed?
 Sxs with left-to-right shunt
 Audible murmur
 Reversible pulmonary HTN
 Left sided volume overload/heart failure
Management Summary
 Premies indomethacin; surgery if
unsuccessful
 Term infants medical treatment to
optimize for percutaneous closure; if this
fails, then surgery
 Children/Adults: in general, percutaneous
closure